Tuberculosis comorbidities, multimorbidity and mortality amongst adults in South Africa: A prospective cohort study nested in a trial
Related Experiment Video
Updated: Aug 7, 2026

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
Published on: April 30, 2020
Greta K Wood1,2,3, Rachel L Byrne1, Limakatso Lebina4,5
1Centre for Tuberculosis Research, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Abstract:
Tuberculosis (TB) comorbidities and multimorbidity - the presence of two or more concurrent diseases or health conditions - are major contributors to TB incidence and mortality. We investigated the prevalence and associated mortality of TB comorbidities and multimorbidity in South Africa. We conducted a prospective cohort study of adults ≥15 years with bacteriologically-confirmed pulmonary TB, nested within a trial in two provinces of South Africa. We investigated five TB key comorbidities (HIV, undernutrition, diabetes, smoking and alcohol use), and assessed all-cause mortality over 15 months using Cox regression. TB comorbidity was defined as TB with one comorbidity, and TB multimorbidity as TB with two or more comorbidities. Of 1997 participants, 1896 (95%) had mortality data available at 15 months. Median age was 38 (IQR 29-48) years, 1203/1997 (60%) were male, 86·2% (95% CI 84·6-86·6) had TB comorbidity and 47·5% (45·3-49·7) had TB multimorbidity. TB comorbidity peaked in participants aged 40-49 years (93% [90-95]), was more prevalent in men vs women (90%[88-91] vs 81%[78-84], p < 0·001), and in urban vs rural areas (88%[86-90] vs 84%[81-86], p = 0·005). Mortality was higher for participants with TB multimorbidity with two (16·0%[13·0-18·8], HR 1·88[1·20-2·95], p = 0·006) and three or more (19·9%[14·9-24·6], HR 2·58[1·56-4·24], p < 0·001) TB key comorbidities than those with no comorbidities (11·2%[7·17-15·0]) or TB comorbidity (10·6% [8·32-12·8]). The joint population attributable fraction for the TB key comorbidities on mortality was 60·0% (49·6-69·2%). TB comorbidities and multimorbidity are highly prevalent and significantly associated with mortality. People with TB should be offered screening and management of comorbidities to reduce their risk of death.
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
